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Background: Amino acid neurotransmitters and nitric oxide (NO) are involved in the pathogenesis of major
depressive disorder (MDD). Here we want to establish whether changes in their plasma levels may serve as
biomarker for the melancholic subtype of this disorder.
Methods: Plasma levels of glutamic acid (Glu), aspartic acid (Asp), glycine (Gly), gamma-aminobutyric acid (GABA),
and NO were determined in 27 medicine-naïve melancholic MDD patients and 30 matched controls. Seven of the
MDD patients participated also in a follow-up study after 2 months’ antidepressant treatment. The relationship
between plasma and cerebral-spinal fluid (CSF) levels of these compounds was analyzed in an additional group of
10 non-depressed subjects.
Results: The plasma levels of Asp, Gly and GABA were significantly lower whereas the NO levels were significantly
higher in melancholic MDD patients, also after 2 months of fluoxetine treatment. In the additional 10
non-depressed subjects, no significant correlation was observed between plasma and CSF levels of these
compounds.
Conclusion: These data give the first indication that decreased plasma levels of Asp, Gly and GABA and increased
NO levels may serve as a clinical trait-marker for melancholic MDD. The specificity and selectivity of this putative
trait-marker has to be investigated in follow-up studies.
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Amino acid neurotransmitters, i.e. the excitatory neuro-
transmitters glutamic acid (Glu) and aspartic acid (Asp),
and the inhibitory neurotransmitters glycine (Gly) and
gamma-aminobutyric acid (GABA), are involved in the
pathogenesis of mood disorders such as major depressive
disorder (MDD) [1,2]. The gaseous neurotransmitter nitric
oxide (NO), which is synthesized from amino acid L-
arginine (Arg) by NO synthases with citrulline (Cit) as a
by-product also plays a significant role in depression [3].* Correspondence: baoaimin@zju.edu.cn
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unless otherwise stated.MDD is thought to be due to the interaction between gen-
etic, early developmental and environmental factors, lead-
ing to an individual’s stress response system becoming
overly responsive to stressful life events, which causes
this system to go into overdrive [4]. The hypothalamo-
pituitary-adrenal (HPA)-axis, the monoamine systems and
the autonomic nervous system are key regulating systems
for stress responses and form major pathways for
symptoms of depression [4,5]. Altered glutamatergic and
reduced GABAergic and NO neurotransmission were ob-
served in depression in a number of brain systems, which
may significantly affect the neuronal activity involved in
stress responses and mood regulation [1,2,6]. Changes in
depression in the levels of these amino acids were found
not only in different brain regions and cerebrospinal fluid
(CSF), but also in blood and urine [7], which implies thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biomarkers or treatment efficacy monitors. Plasma levels
of NO metabolites, i.e. nitrite and nitrate, which reflect the
plasma NO concentrations, were also reported to increase
in depression [8,9]. So far there are, however, quite some
inconsistent findings concerning the plasma amino acid
levels in depression. Decreased [10], increased [11], or no
changes in plasma Gly [12] were reported in depression. In
addition, no alteration [10] or increase in plasma Glu [11]
was observed in depression. These controversial results
may be due, at least partly, to the variety of depression sub-
types studied, and to confounding factors such as different
gender-ratios of samples, and/or different treatments.
Furthermore, amino acid transporter systems are located
in the blood brain barrier (BBB) and transport amino acids
from the blood into the brain and vice versa [13]. It is at
present, however, not clear whether there is a relationship
between the plasma and the CSF levels of these amino
acids, although some researchers have proposed that the
plasma levels of these neuroactive amino acids might, to a
certain degree, reflect their brain levels [2,14].
The present study aimed, therefore, to analyze the
plasma levels of 4 neuroactive amino acids, i.e. Asp, Glu,
Gly and GABA, and NO levels calculated as Cit/Arg [15]
in the major subgroup of melancholic MDD, medicine-
naïve patients in their first depressive episode, in relation
to their clinical symptoms. In addition, the relationship
between plasma and CSF levels of these amino acids was
analyzed in a group of non-depressive patients.
Methods
Subjects
Thirty Chinese Han race MDD patients and 30 age- and
sex-matched control subjects had been recruited in the
study by the Department of Psychiatry of the Second
Affiliated Hospital of Zhejiang University School of
Medicine. Three out of the 30 MDD patients appeared,
however, later to develop bipolar disorder (BD). There-
fore, 27 MDD patients (14 medicine-naïve males and 13
medicine-naïve females, age range 30 to 68 years) who
were in their first depressive episode participated in the
present study. They were diagnosed as melancholic
MDD according to the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM-IV) by qualified
psychiatrists. The Mini International Neuropsychiatric
Interview (Chinese modified version) was used to con-
firm the DSM-IV diagnosis. The 24-item Hamilton De-
pression Scale (HAMD) was used to rate the severity of
depression, and a score of 35 or above was considered to
be severe depression [16]. Seven out of the 27 melan-
cholic MDD patients had suicidal thoughts, 7 attempted
suicide before they joined the study and 1 actually com-
mitted suicide and died after one month of the treat-
ment. Twelve out of the 27 melancholic MDD patientshad no suicidal thoughts. The exclusion criteria were,
apart from BD, as follows: psychiatric co-morbidity in
the form of substance abuse disorders, psychotic disor-
ders, anxiety disorders or mental retardation, chronic
physical illness, or abnormal body mass index (BMI ≤ 18
or BMI ≥ 25). The follow-up protocol was as follow: after
2 months of antidepressant treatment (fluoxetine 20-40
mg/day) the patients came back to the clinic and their
symptoms and HAMD scores were evaluated again,
together with their blood samples being taken. Seven
(6 males and 1 female) out of the 27 melancholic MDD
patients whose clinical symptoms had improved and
whose HAMD scores were at that moment lower than
14 (data not shown) voluntarily joined the follow-up
study. The 30 healthy control subjects (15 males and 15
females, age range 30 to 65 years) who underwent their
yearly physical examination in the same hospital volun-
tarily participated in this study during the same period.
The exclusion criteria for the controls were as follows:
abnormal BMI, medication for chronic illnesses or men-
tal disorders.
Ten additional patients (4 males and 6 females, age
range 20 to 68 years) with a range of medical conditions,
including stroke, uterus with scar, leukemia, brainstem
hemorrhage, and subarachnoid haemorrhage, and whose
CSF and plasma samples were obtained for clinical rea-
sons within the same hour, voluntarily participated in
the present study during their stay in the same hospital.
They were all during their clinical recovery phase. The
inclusion criteria for this group were as follows: color-
less, transparent CSF, leukocyte cell count < 100 × 106/L,
red cell count < 100 × 106/L. The exclusion criteria for
this group were as follows: abnormal BMI and/or psy-
chiatric disorders.
The investigation was carried out in accordance with the
latest version of the Declaration of Helsinki. All subjects
signed informed consent forms and the study was ap-
proved by the Medical Ethics Committee of the Second
Affiliated Hospital of Zhejiang University School of Medi-
cine. Venous blood samples or CSF samples were collected
between 6:00 a.m. and 9:00 a.m., and frozen at -80°C until
measured.
High performance liquid chromatography (HPLC) with
fluorescence detection (FLD) for plasma and CSF amino
acid analysis
The plasma (1 ml) and CSF (1-1.5 ml) samples were
deproteinized with acetonitrile (1:1 v/v), lyophilized and
diluted with 60% (v/v) methanol before analysis.
The plasma or CSF amino acid levels were determined by
HPLC, which included pre-column derivatization with o-
phthalaldehyde (Cat: O120, Pickering Laboratories, Inc.
USA) and 3-mercaptopropionic acid (MPA, CAS: 107-96-0,
Acros Organics, NJ, USA), reverse phase separation with
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nologies, Santa Clara, CA, USA). Two mobile phases were
applied to the detection. The linearity of the detector
response to standards was in the range of 13.2-79.0 μmol/
L (Asp), 10.2-1447.0 μmol/L (Glu), 85.7-1000.0 μmol/L
(Gly), 0.3-142.3 μmol/L (GABA), 0.9-158.2 μmol/L (Cit)
and 1.8-178.0 μmol/L (Arg). The intraday relative standard
deviations for the peak area were as follows: Asp, 2.27%;
Glu, 2.14%; Gly, 1.59%; GABA, 3.89%, Cit, 0.97%; Arg,
0.77%, respectively. The interday relative standard devia-
tions for the peak area were as follows: Asp, 2.69%; Glu,
6.37%; Gly, 4.29%; GABA, 6.62%, Cit, 4.29%; Arg, 3.18%,
respectively.
Statistical analysis
As the data were found to be not always normally dis-
tributed, non-parametric tests were applied. Comparison
among 3 groups was performed by Kruskal-Wallis H
test. Comparison between 2 groups was performed by
Mann-Whitney U test. Comparison between 2 related
samples was analyzed by Wilcoxon test. Correlations
were examined with the Spearman test. P < 0.05 was
considered to be significant.
Results
The melancholic MDD group showed significantly de-
creased levels of plasma Asp (73.1%), Gly (39.9%), and
GABA (36.6%), and significantly increased levels of NO
(21.2%) compared with the control group (P = 0.003, P <
0.001, P = 0.021, and P = 0.005, respectively; Figure 1).Figure 1 Changes of plasma levels of neuroactive amino acids, and n
major depressive disorder. Boxplot showing the median, 25th-75th perce
acid; (B): Gly, glycine; (C): GABA, gamma-aminobutyric acid; (D): NO, nitric o
**P <0.01, ***P <0.001.No changes were found in plasma Glu levels (P = 0.646). In
addition, there were significant positive correlations be-
tween Glu and Asp, and between GABA and Gly (rho =
0.756, P = 0.000; and rho = 0.479, P = 0.011; respectively),
and a significant negative correlation between NO and
Asp (rho = - 0.453, P = 0.018) in these MDD patients.
When the relationships of the plasma levels of these 4
amino acids or NO levels and the different sub-phenotypes
of the 9 symptoms of MDD according to the DSM-IV were
checked (Table 1), it was observed that MDD patients who
lost interest/pleasure or who had suicide thoughts had
trends for higher plasma GABA levels (P = 0.076, and P =
0.054, respectively). The HAMD scores showed no signifi-
cant correlations with these amino acid nor with the NO
plasma levels (P ≥ 0.137). There were also no significant
differences for the amino acid or NO levels between those
with HAMD scores above 35 and those with HAMD
scores below 35 (P ≥ 0.246). Moreover, for the 7 MDD pa-
tients who participated in the follow-up test, no significant
differences were found for these amino acids or NO
plasma levels before and after fluoxetine treatment (P ≥
0.128, Figure 2).
The melancholic MDD patients showed no sex differ-
ences in these amino acids or NO plasma levels (P ≥
0.275). However, the subjects in the control group showed
a significant sex difference in plasma Glu levels: male sub-
jects had a significant 66.6% higher Glu level than female
subjects (P = 0.003), which was not seen for Asp, Gly,
GABA or NO levels (P ≥ 0.206). In addition, a significant
positive correlation was observed between plasma levels ofitric oxide (NO, calculated as citruline/arginine) in melancholic
ntiles, and maximum and minimum value range. (A): Asp, aspartic
xide. CTR, control; MDD, major depressive disorder.
Table 1 Comparison of plasma amino acids levels and nitric oxide levels in the 9 symptoms of major depressive
disorder according to the DSM-IV
Symptom items Subgrouping Asp Glu Gly GABA NO
Item 1: depressed mood No: n = 0
∕ ∕ ∕ ∕ ∕
Yes: n = 27
Item 2: diminished interest No: n = 3
0.643 0.841 0.700 0.076 0.817
Yes: n = 24
Item 3: weight loss No: n = 13
0.382 0.898 0.438 0.645 0.382Weight gain: n = 0
Weight loss: n = 14
Item 4: disordered psychomotor state No change: n = 4
0.417 0.450 0.883 0.985 0.346Agitation: n = 10
Retardation: n = 13
Item 5: disordered sleep No: n = 1
0.847 0.616 0.773 0.312 0.211Hypersomnia: n = 2
Insomnia: n = 24
Item 6: fatigue or loss of energy No: n = 9
0.382 0.647 0.643 0.396 0.607
Yes: n = 18
Item 7: feeling of worthlessness or guilt No: n = 11
0.374 0.775 0.402 0.711 0.693
Yes: n = 16
Item 8: diminished ability to think or concentrate, or indecisiveness No: n = 9
0.837 0.617 0.719 0.662 0.090
Yes: n = 18
Item 9: thought of death or suicide No: n = 12
0.118 0.504 0.495 0.054 0.558
Yes: n = 15
Notes: Comparison of plasma levels of the 4 amino acids or NO levels among different sub-phenotype groups, based upon the 9 symptoms of major depressive
disorder according to the DSM-IV. No: without this symptom; Yes: with this symptom. The numbers in the Table are P values. Comparison among 3 subgroups
was performed by Kruskal -Wallis H test. Comparison between 2 subgroups was performed by Mann-Whitney U test. Asp: aspartic acid; Glu: glutamic acid; Gly:
glycine; GABA: gamma-aminobutyric acid; NO: nitric oxide. The 9 symptoms includes: 1. depressed mood most of the day, nearly every day, as indicated by either
subjective report (e.g. feels sad or empty) or observation made by others (e.g. appears tearful); 2. markedly diminished interest or pleasure in all, or almost all,
activities most of the day, nearly every day (as indicated by either subjects account or observation made by others); 3. significant weight loss when not dieting or
weight gain (e.g. a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day; 4. psychomotor agitation or
retardation nearly every day (observable by others, not merely subjective feelings of restless or being showed down); 5. insomnia or hypersomnia nearly every
day; 6. fatigue or loss of energy nearly every day; 7. feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) near every day (not
merely self-reproach or guilt about being sick); 8. diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as
observed by others); 9. recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific
plan for committing suicide.
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GABA (P = 0.0001, P = 0.002, P = 0.017, and P = 0.041,
respectively). No significant correlation was observed
between plasma levels of these amino acids and NO
(P ≥ 0.470).
In the additional 10 non-depressive patients who were
during their clinical recovery phase no significant corre-
lations were found between plasma and CSF levels of
Asp, Gly, GABA and NO (P ≥ 0.511), although there was
a trend towards a positive correlation between plasma
and CSF levels of Glu (rho = 0.588, P = 0.074).
Discussion
In the present study we determined the plasma levels of
4 neuroactive amino acids, i.e. Asp, Glu, Gly and GABA,
and of NO levels in medicine-naïve melancholic MDD
patients in their first depressive episode. Significantlylower levels of Asp, Gly and GABA, and significantly
higher levels of NO, which endured after 2 months of
fluoxetine treatment, were observed in these patients, in-
dicating that they might serve as a trait-marker, rather
than a state-marker, for melancholic MDD. The fact that
none of these parameters showed a clear correlation
with HAMD scores or with the severity of depression
fits the idea of a potential trait-marker.
Our finding of decreased plasma GABA levels in melan-
cholic MDD was consistent with previous reports, which,
in general, showed a significant decrease in GABA levels
in plasma, CSF and brain tissue (for review, see [2]). In the
7 melancholic MDD patients whose clinical symptoms im-
proved and who had agreed on repeated measurement we
did not find significant changes in the GABA levels after 2
months of fluoxetine treatment. These data are in agree-
ment with previous studies reporting that the decreased
Figure 2 Plasma levels of neuroactive amino acids and nitric oxide (NO) in melancholic major depressive disorder before and after 2
months of fluoxetine antidepressant treatment (20-40 mg/day). (A): Asp, aspartic acid; (B): Gly, glycine; (C): GABA, gamma-aminobutyric acid;
(D): NO, nitric oxide. MDD, major depressive disorder. Please note that there is no change in spite of the treatment (P≥ 0.128).
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by the mood states, the severity of depressive symptoms
or the antidepressant treatment [2]. It is noteworthy that
in one study electroconvulsive therapy (ECT) showed no
significant effect on plasma Gly but did result in increased
plasma Asp and decreased plasma GABA levels in de-
pressed patients [17]. The fact that ECT may significantly
change the permeability of the BBB [18] may explain these
alterations. It was interesting to see, however, that when
we subgrouped these melancholic MDD patients accord-
ing to each of the 9 symptoms of MDD (Table 1), we ob-
served that those who lost interest/pleasure or who had
suicide thoughts had trends for higher plasma GABA
levels, although the MDD patients as a whole group
showed lower GABA levels than controls. This point has
to be investigated further in the future in a larger cohort
of patients.
To our knowledge, this is the first report of a significant
decrease in plasma Asp levels in medicine-naïve melan-
cholic MDD patients. Altamura et al. [10] reported that
there was no significant alteration of plasma Asp levels in
untreated depressed patients. It should be noted, however,
that their patients included BD subjects, while there was a
study showing a significant increase both in plasma Glu
and Gly in BD patients during the manic phase [19].
Mauri et al. [12] also reported no significant changes in
plasma Asp and Gly levels, but they studied non-
melancholic MDD patients. That Mauri et al. did not find
changes in the plasma amino acid levels after 2 months of
fluoxetine treatment was, however, in agreement with ourpresent study. Please note that the sex difference in
plasma Glu levels may have contributed to the discrepancy
with these studies since the samples involved contained
different gender-ratios.
The present results of increased plasma NO levels in
melancholic MDD patients are consistent with a number
of previous reports [8,9], which also found elevated NO
plasma levels in MDD patients. It should be noted that
these reports indicated that increased plasma levels of
NO might be accompanied with suicide attempts in
these patients [8,9], which was not observed in the
present study. Interestingly, we found a significant nega-
tive correlation between the plasma levels of NO and
Asp in melancholic MDD, which is consistent with the
findings that testosterone levels are changed in MDD
[20], and that NO inhibits whereas Asp promotes testos-
terone levels [21,22].
Some putative causes of the observed changes in plasma
levels of neuroactive amino acids and NO in melancholic
MDD should be considered. The HPA-axis and the auto-
nomic nervous system are activated in stress responses and
in depression. It was found in rats that activation of the
sympathetic nervous system may lead to decreases in
plasma Glu levels [23] due to significant increases in 2 en-
zymes, i.e. glutamate pyruvate transaminase and glutamate-
oxaloacetate transaminase, which may accelerate the
conversion of Glu to 2-ketoglutarate [24]. In addition,
the stress compounds corticotrophin-releasing hormone
(CRH) and adrenaline have been demonstrated to sig-
nificantly and consistently decrease blood Glu levels in
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nificantly higher plasma levels of CRH in melancholic
MDD patients compared with healthy controls (unpub-
lished data). Whether the hyperactive HPA-axis and the
sympathetic nervous system are involved in the mech-
anism which decreases the plasma levels of the amino
acids Asp, Gly and GABA warrants further study. It is
also known that stress-related events, including depres-
sion, are characterized by modifications of oxidative/
nitrosative pathways in the brain [26]. Considering the
important role of NO in oxidative stress [27], our find-
ing of significantly increased plasma NO levels appear
to at least partially corroborate the stress theory of
depression. Furthermore, these neuroactive amino acids
are non-essential amino acids that the body could
synthesize by itself. Melancholic MDD patients have a
decreased appetite, and thus also decreased food intake,
leading to a reduced metabolism and decreased synthe-
sis of these amino acids. This is also the reason why we
limited the range of BMIs in the present study. Finally,
BBB permeability may be changed in pathological con-
ditions, as it does in the case of vascular brain edema
and brain tumors [13], thus affecting the transportation
between the brain and the blood of amino acid neuro-
transmitters. However, such BBB changes have, as far as
we know, not been reported in MDD.
The study on the relationship between plasma and
CSF levels of amino acids was carried out in a group of
non-depressed individuals with different diseases who
were during their clinical recovery phase. It is a limita-
tion of present study that, for ethical reasons, we could
not study CSF from MDD patients or healthy control
subjects. It cannot be excluded that the medical condi-
tions from which these patients were recovering may
have affected BBB function. It should be noted, however,
that the absence of correlations that we found between
plasma and CSF amino acid levels is in agreement with
the report that there were no significant correlations
between venous blood and CSF levels of Asp or Gly in
healthy subjects [28]. This implies that the 2 compart-
ments, i.e. the blood and the CSF, do not seem to have
an equilibrium mechanism for the transportation of
these amino acid neuroactive substances. Another limi-
tation of the present study is that the study was based
upon a relatively limited sample size and only 7 patients
finished the follow-up study. It should be noted, how-
ever, that although the number of followed up patients is
relatively small, the Wilcoxon test for these 7 patients,
that showed significant clinical improvement after 2
months antidepressant treatment, did not show signifi-
cant changes in these amino acids or NO plasma levels
before and after treatment, which supports the sugges-
tion that these parameters might serve as trait-markers
for melancholic subtype of MDD.Conclusion
Melancholic MDD patients have significantly decreased
plasma levels of Asp, Gly and GABA and increased NO
levels. Larger patient groups and other types of MDD
should be investigated before we can conclude that
indeed the changes in the plasma neuroactive amino
acids and NO are trait-, rather than state-, marker for
melancholic MDD.
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